Lists TaqMan Gene Expression Assays used in the study. Table S2 shows sequence of primers and PCR conditions used for promoter CpG methylation profiling. Table S3 shows results of stage-adjusted Cox regression of associations between transcript levels and DFI of colorectal cancer patients from the combined testing and validation I sets. Figure S1 depicts 5-Fluorouracil pathway gene expression levels in the studied sets of colorectal cancer patients. Figure S2 shows results of analysis of associations between transcript levels and disease-free survival of colorectal cancer patients from the validation set I. Figure S3 shows results of analysis of associations between transcript levels and disease-free survival of colorectal cancer patients from the testing set. Figure S4 shows results of analysis of associations between transcript levels and disease-free survival of colorectal cancer patients from the combined testing and validation I set. Figure S5 shows results of analysis of associations between transcript levels and disease-free survival of 5-fluorouracil-treated colorectal cancer patients from the combined testing and validation I set. Figure S6 shows results of analysis of associations between transcript levels and disease-free survival of untreated colorectal cancer patients from the validation I set. Figure S7 shows results of analysis of associations between UPB1 methylation levels and disease-free survival of colorectal cancer patients. Figure S8 shows analysis of association of RRM2 expression with disease-free survival of colorectal cancer patients based on publicly available GEO database. Figure S9 shows analysis of methylation profiles of 5-FU pathway genes in human colorectal tumor (red boxes) and mucosa (green boxes) tissues from publicly available MethHC database. (DOC 1916Â kb